亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma

医学 阿帕蒂尼 替莫唑胺 内科学 黑色素瘤 肿瘤科 皮肤病科 化疗 总体生存率 癌症研究
作者
Lili Mao,Bin Lian,Caili Li,Xue Bai,Li Zhou,Chuanliang Cui,Zhihong Chi,Xinan Sheng,Xuan Wang,Bixia Tang,Xieqiao Yan,Siming Li,Yan Kong,Jie Dai,Xiaoting Wei,Juan Li,Rong Duan,Huayan Xu,Xiaowen Wu,Yue Yang
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:9 (8): 1099-1099 被引量:34
标识
DOI:10.1001/jamaoncol.2023.1363
摘要

Importance: Acral melanoma, known for low tumor mutation burden, responds poorly to immunotherapy. A standard therapy is still lacking. Objective: To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma. Design, Setting, and Participants: In this single-arm, single-center, phase 2 nonrandomized clinical trial, patients with treatment-naive unresectable stage III or IV acral melanoma were enrolled at Peking University Cancer Hospital and Institute between June 4, 2020, and August 24, 2021. The data cutoff date was April 10, 2022. Interventions: Patients received 4-week cycles of intravenous camrelizumab, 200 mg, every 2 weeks; oral apatinib 250 mg, once daily; and intravenous temozolomide, 200 mg/m2, once daily on days 1 to 5 until disease progression or unacceptable toxic effects. Main Outcomes and Measures: The primary end point was objective response rate as assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (version 1.1). Secondary end points included progression-free survival, time to response, duration of response, disease control rate, overall survival, and safety. Results: A total of 50 patients (32 men [64%]; median age, 57 years [IQR, 52-62 years]) were enrolled and received treatment. The median follow-up duration was 13.4 months (IQR, 9.6-16.2 months). The objective response rate was 64.0% (32 of 50; 95% CI, 49.2%-77.1%). The median time to response and duration of response were 2.7 months (IQR, 0.9-2.9 months) and 17.5 months (95% CI, 12.0 to not reached), respectively. The disease control rate was 88.0% (44 of 50; 95% CI, 75.7%-95.5%). The estimated median progression-free survival was 18.4 months (95% CI, 10.6 to not reached). The median overall survival was not reached. The most common grade 3 or 4 treatment-related adverse events were increased gamma-glutamyltransferase levels (15 [30%]), decreased neutrophil count (11 [22%]), increased conjugated bilirubin levels (10 [20%]), and increased aspartate aminotransferase levels (10 [20%]). No treatment-related deaths occurred. Conclusions and Relevance: The findings of this nonrandomized clinical trial suggest that camrelizumab plus apatinib and temozolomide may be a potential first-line treatment option for patients with advanced acral melanoma, which warrants further validation in a randomized clinical trial. Trial Registration: ClinicalTrials.gov Identifier: NCT04397770.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dolabmu完成签到 ,获得积分10
1秒前
魔幻雅柔完成签到,获得积分10
2秒前
月亮打烊完成签到 ,获得积分10
5秒前
文静楷瑞完成签到,获得积分10
8秒前
fx完成签到 ,获得积分10
10秒前
10秒前
fantasy的应助被十三采纳,获得10
11秒前
深情安青的应助被outlast采纳,获得10
16秒前
十三完成签到,获得积分10
17秒前
18秒前
22秒前
拼搏问薇完成签到 ,获得积分10
23秒前
24秒前
Abcqqq完成签到 ,获得积分10
24秒前
海洋球完成签到,获得积分10
26秒前
ll完成签到,获得积分20
26秒前
小蘑菇的应助被xx2026采纳,获得10
27秒前
28秒前
kxz完成签到 ,获得积分10
28秒前
29秒前
gale发布了新的文献求助10
32秒前
红墨发布了新的文献求助30
33秒前
35秒前
怕黑的驳完成签到,获得积分10
36秒前
38秒前
39秒前
40秒前
41秒前
吐司发布了新的文献求助10
42秒前
冷静新烟完成签到,获得积分10
42秒前
gale完成签到,获得积分10
45秒前
50秒前
50秒前
TIDUS完成签到,获得积分10
52秒前
独特的念柏完成签到,获得积分10
56秒前
sadascaqwqw发布了新的文献求助10
56秒前
36hours完成签到,获得积分10
57秒前
田様的应助被冷静新烟采纳,获得10
57秒前
58秒前
Ava的应助被典雅的可乐采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195004
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872554
捐赠科研通 7794720
什么是DOI,文献DOI怎么找? 3437836
关于科研通互助平台的介绍 2561159
邀请新用户注册赠送积分活动 2484541